AstraZeneca PLC ( AZN ) offers a current dividend yield of approximately 1.56%, below the pharmaceutical industry average but supported by a progressive policy. Annual dividend stands at $3.20 per share, paid semi-annually, with the most recent second interim dividend of $2.17 per share.

NVS stock declined -4% over the past 30 days amid sector-wide pressures from proposed pharmaceutical tariffs and profit-taking after a peak near $164. Over the past quarter, the stock rose +10%, supported by strong Q4 earnings beat, pipeline advancements, and strategic acquisitions.

AbbVie Inc. (ABBV) stands out as a research-based biopharmaceutical company dedicated to developing and commercializing therapies across immunology, oncology, neuroscience, eye care, and aesthetics. At its core, the company's business model relies on a diversified portfolio of blockbuster drugs, with immunology standouts like Skyrizi (risankizumab) and Rinvoq (upadacitinib) fueling growth following the Humira patent expiration.

Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.

LLY stock declined -13% over the past 30 days amid concerns over obesity drug pricing pressures and competition from NVO. Over the past quarter, the stock fell around -17%, despite strong Q4 2025 earnings driven by Mounjaro and Zepbound volume growth. Bearish analyst notes on market saturation and potential price wars outweighed positive trial data for next-gen drugs like retatrutide.

Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.

Q4 2025 revenue reached $12.5 billion, exceeding expectations, with growth portfolio sales up 16% year-over-year. Full-year 2025 revenue totaled $48.2 billion, supported by Eliquis, Opdivo, and newer products including Breyanzi and Camzyos.

Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.

Gilead Sciences (GILD): Q4 2025 earnings due February 10, consensus EPS $1.83, revenue $7.68B. Growth driven by HIV franchise; oncology investments like Trodelvy may offer upside. Amgen (AMGN): Reported Q4 2025 EPS $5.29 vs $4.73 expected, revenue $9.9B (+9% YoY). Strong 2026 guidance: $37–38.4B revenue, $21.60–23.00 non-GAAP EPS.

Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.

(AZN) AstraZeneca’s full-year 2025 results, set for February 10, 2026, cap a year of sustained growth amid competitive pressures. Following 21% total revenue growth in FY 2024 and 19% core EPS expansion, AZN has maintained momentum with 11% revenue growth through nine months of 2025. The report offers insight into:

Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns

Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.

Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.

Eli Lilly and Novo Nordisk are among the most influential pharmaceutical companies in the rapidly expanding GLP-1 receptor agonist market, which targets diabetes and obesity. As competition intensifies and regulatory and pricing dynamics evolve, the divergence in their stock performance has become increasingly pronounced.

A wave of industry leaders—including GOOGL, LLY, JNJ, ALB, and SQM—hit fresh 52-week highs on November 19, 2025, as bullish momentum swept through tech, healthcare, retail, and commodities. Backed by earnings strength, sector tailwinds, and macroeconomic stability, the market rally highlights renewed investor appetite for growth. Tickeron’s AI robots further confirm the momentum, identifying high-probability signals across these surging names.

Verona Pharma's stock soared 122% in just three months, culminating in Merck's $10 billion acquisition. Learn how breakthrough COPD drug Ohtuvayre, stellar sales growth, and expert execution transformed this biotech into a blockbuster success.

ntroduction to Eli Lilly and Company (LLY) Eli Lilly and Company (LLY), a global pharmaceutical giant, has been a cornerstone of the healthcare sector since its founding in 1876. Headquartered in Indianapolis, Indiana, the company specializes in developing innovative treatments for diabetes, oncology, immunology, and neuroscience, with blockbuster drugs like Mounjaro and Zepbound driving significant…

The Tickeron quant team is delighted to introduce our top-performing AI robot tailored for beginners. Our AI Robot specializes in navigating the high-tech stocks within the NASDAQ 100 index, renowned for their liquidity and moderate volatility—making them an ideal choice for novice traders.

The Tickeron quant team is excited to introduce our premier AI robot, specifically optimized for Swing Traders. This tool represents the pinnacle of our technological advancements in trading algorithms. Excelling in the market, it has achieved an impressive feat, earning twice as much as the S&P 500 in just the past week.